Trandolapril: a clinical profile

Area of Science:

• Pharmacology
• Cardiovascular Medicine
• Nephrology

Background:

• Angiotensin converting enzyme (ACE) inhibitors are crucial in managing hypertension.
• Trandolapril is a novel ACE inhibitor with a unique pharmacokinetic profile.
• Understanding its efficacy and safety is vital for clinical practice.

Purpose of the Study:

• To evaluate the efficacy and safety of trandolapril in lowering blood pressure.
• To investigate the pharmacokinetic properties of trandolapril and its active metabolite, trandolaprilat.
• To determine the impact of renal function on trandolaprilat clearance.

Main Methods:

• Clinical trials assessing blood pressure reduction with trandolapril.
• In vivo studies on the transformation of trandolapril to trandolaprilat.
• Correlation analysis between trandolaprilat clearance and creatinine clearance.

Main Results:

• Trandolapril effectively lowers blood pressure up to 2 mg, with minimal additional benefit at higher doses.
• Trandolaprilat is the active metabolite, and its clearance is linked to creatinine clearance, necessitating dose reduction in severe renal impairment.
• Sustained ACE inhibition and blood pressure control in approximately 60% of patients.
• Trandolapril exhibits a comparable side effect profile to other ACE inhibitors and is safe for prolonged use.

Conclusions:

• Trandolapril is an effective and safe antihypertensive agent, particularly at doses up to 2 mg.
• Renal function monitoring and potential dose adjustment are important for patients with impaired renal function.
• The sustained action and favorable safety profile support the long-term use of trandolapril in managing hypertension.